Huang et al. (27) subsequently described the case of a 61-year-old patient with stage IIIA (cT2N2M0) NSCLC harboring BRAF V600E and SETD2 co-mutations, PD-L1 expression of 80%, microsatellite stable status (MSS), and a tumor mutational burden (TMB) of 1 mut/Mb. Here, SETD2 is linked to neoplasm.